Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response

Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH

Read more at globenewswire.com